In a significant move to enhance cancer care across the Middle East and North Africa (MENA), Shilpa Biologicals Private Limited has entered into an exclusive strategic licensing and commercialization agreement with Saudi Arabia’s SPIMACO Bio. The partnership aims to bring a suite of PD-1 inhibitor biosimilars to the region, marking a major step forward in addressing the rising prevalence of cancer through more affordable, high-quality immunotherapy.
Under the terms of the agreement, Shilpa Biologicals will retain all intellectual property rights and will serve as the exclusive developer and manufacturer of the biosimilars. The company is set to receive a structured financial package that includes upfront payments, development and commercial milestone payments, and consistent revenue generated through product supply. Meanwhile, SPIMACO Bio will leverage its established regional infrastructure to lead commercialization, regulatory execution, and market access strategies throughout the MENA territory.
PD-1 inhibitors represent a critical frontier in modern oncology. By assisting the immune system in identifying and attacking tumor cells, these therapies have become standard treatments for a diverse range of cancer types. As cancer rates climb across the Middle East, the partnership seeks to bridge the gap in healthcare affordability and patient access, combining Shilpa’s robust, integrated manufacturing capabilities with SPIMACO Bio’s deep regional presence.
Beyond commercial distribution, the collaboration includes a visionary phased technology transfer program. This initiative is designed to establish localized manufacturing of the biosimilars within Saudi Arabia. By building this capacity, the companies aim to strengthen regional supply chain security and foster high-value biomanufacturing expertise. This effort directly supports the localization objectives outlined in Saudi Vision 2030, underscoring a commitment to creating a more self-reliant and resilient regional healthcare ecosystem.
“This partnership creates significant long-term value for Shilpa Biologicals while advancing our mission to make world-class biologic medicines accessible to patients wherever they live,” said Madhav Bhutada, Director of Shilpa Biologicals. “This agreement demonstrates Shilpa Biologicals’ ability to develop, manufacture, and transfer complex biologics to global partners… and through a future technology transfer, we will also help build durable local manufacturing capability for the region.”
For SPIMACO Bio, the deal represents a fulfillment of its strategic mandate to prioritize advanced healthcare solutions. Prof. Ahmed Al-Jedai, Vice Chairman and Managing Director of SPIMACO Bio, emphasized the importance of the collaboration, noting that the scientific depth and GMP-compliant manufacturing prowess of Shilpa Biologicals make them the ideal partner to navigate the complex regulatory and commercial landscape of the region.
As both organizations move toward the implementation phase, the agreement stands as a testament to the power of international cooperation in biotechnology, promising a future where cutting-edge cancer immunotherapies are no longer a luxury, but a standardized, accessible component of regional healthcare.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
